6533b853fe1ef96bd12ad61f
RESEARCH PRODUCT
The Carbon Monoxide-Releasing Molecule Tricarbonyldichlororuthenium(II) Dimer Protects Human Osteoarthritic Chondrocytes and Cartilage from the Catabolic Actions of Interleukin-1β
Antonio BruMaría José AlcarazJavier MegíasMaria Isabel GuillénFrancisco Gomarsubject
MaleInterleukin-1betaDown-RegulationMatrix metalloproteinaseProtective AgentsProinflammatory cytokineExtracellular matrixChondrocytesOsteoarthritisOrganometallic CompoundsmedicineExtracellularHumansAggrecansCollagen Type IIAggrecanAgedPharmacologyCarbon MonoxideThrombospondinChemistryCartilageADAMTSMatrix MetalloproteinasesCell biologyCartilagemedicine.anatomical_structureBiochemistryMolecular MedicineFemaledescription
We have investigated the effects of a carbon monoxide-releasing molecule, tricarbonyldichlororuthenium(II) dimer (CORM-2), on catabolic processes in human osteoarthritis (OA) cartilage and chondrocytes activated with interleukin-1beta. In these cells, proinflammatory cytokines induce the synthesis of matrix metalloproteinases (MMPs) and aggrecanases, including members of a disintegrin and metalloproteinase with thrombospondin domain (ADAMTS) family, which may contribute to cartilage loss. CORM-2 down-regulated MMP-1, MMP-3, MMP-10, MMP-13, and ADAMTS-5 in OA chondrocytes, and it inhibited cartilage degradation. These effects were accompanied by increased aggrecan synthesis and collagen II expression in chondrocytes. Our results also indicate that the inhibition of extracellular signal-regulated kinase 1/2 and p38 activation by CORM-2 may contribute to the maintenance of extracellular matrix homeostasis. These observations suggest that CORM-2 could exert chondroprotective effects due to the inhibition of catabolic activities and the enhancement of aggrecan synthesis.
year | journal | country | edition | language |
---|---|---|---|---|
2008-01-16 | Journal of Pharmacology and Experimental Therapeutics |